Case Study: Llaama accelerates AI-driven biopharma treatments with Akka

Llaama helps biopharma companies bring new treatments to market faster with Akka

Llaama, a biopharma company building AI-driven treatments, chose Akka as the foundation for its T2R2 solution to overcome the complexity of building distributed, event-driven systems and data lineage infrastructure on its own. The company needed a way to make AI and research pipelines traceable, transparent, replicable, and reproducible while avoiding months of DevOps and database work.

Akka helped Llaama implement T2R2 with distributed data analysis and AI pipelines, immutable audit trails, end-to-end observability, and flexible data contracts. The result is a cryptographically verifiable lineage of every event and a smoother, faster workflow for research and regulatory reuse, helping reduce errors, improve collaboration, and accelerate drug development.

Llaama

Bernard Deffarges

Co-founder and CEO